Teriparatide therapy and beta-tricalcium phosphate enhance scaffold reconstruction of mouse femoral defects

Tissue Engineering - Part A

Volumn 17, Issue 3-4, 2011, Pages 389-398

  Jacobson, Justin A ^a   Yanoso Scholl, Laura ^a,b   Reynolds, David G ^a,b   Dadali, Tulin ^a   Bradica, Gino ^c   Bukata, Susan ^a   Puzas, Edward J ^a   Zuscik, Michael J ^a   Rosier, Randy ^a   O'Keefe, Regis J ^a   Schwarz, Edward M ^a   Awad, Hani A ^a,b  

^a The Center for Musculoskeletal Research   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Kensey Nash Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIALS; BIOMECHANICS; BONE; COMPUTERIZED TOMOGRAPHY; DEFECTS; LACTIC ACID; RIGIDITY; SILICATE MINERALS; TRANSMISSION CONTROL PROTOCOL;

BETA TRICALCIUM PHOSPHATE; BONE MINERAL CONTENT; BONE REGENERATION; BONE UNION; BONE VOLUME; C57BL/6 MICE; CALLUS FORMATION; CONTROL LEVEL; LOW POROSITY; MICROCOMPUTED TOMOGRAPHY; MINERAL CONTENT; PARATHYROID HORMONES; POLY LACTIC ACID; STERILE SALINE; STRUCTURAL RIGIDITY; TORSIONAL STRENGTH;

SCAFFOLDS;

MUS;

BETA-TRICALCIUM PHOSPHATE; CALCIUM PHOSPHATE; PARATHYROID HORMONE[1-34]; TISSUE SCAFFOLD;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE PROSTHESIS; FEMALE; FEMUR FRACTURE; MOUSE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; BONE SUBSTITUTES; CALCIUM PHOSPHATES; COMBINED MODALITY THERAPY; FEMALE; FEMORAL FRACTURES; MICE; MICE, INBRED BALB C; TERIPARATIDE; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 79551551965     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2010.0115     Document Type: Article

References (47)

1. Akkus, O., and Rimnac, C.M. Fracture resistance of gamma radiation sterilized cortical bone allografts. J Orthop Res 19, 927, 2001.
2. Hutmacher, D.W. Scaffolds in tissue engineering bone and cartilage. Biomaterials 21, 2529, 2000.
3. Bonadio, J., Smiley, E., Patil, P., and Goldstein, S. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 5, 753, 1999.
4. Chen, H., Frankenburg, E.P., Goldstein, S.A., and McCauley, L.K. Combination of local and systemic parathyroid hormone enhances bone regeneration. Clin Orthop Relat Res 416, 291, 2003.
5. Holick, M.F. PTH (1-34): a novel anabolic drug for the treatment of osteoporosis. South Med J 98, 1114, 2005.
6. Deal, C., and Gideon, J. Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis. Cleve Clin J Med 70, 585, 589, 592 passim, 2003.
7. Reeve, J. PTH: a future role in the management of osteoporosis? J Bone Miner Res 11, 440, 1996.
8. Kaback, L.A., Soung, D.Y., Naik, A., Geneau, G., Schwarz, E.M., Rosier, R.N., et al. Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem 105, 219, 2008. 9.
9. Alkhiary, Y.M., Gerstenfeld, L.C., Krall, E., Westmore, M., Sato, M., Mitlak, B.H., et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87, 731, 2005.
10. Puzas, J.E., Houck, J., and Bukata, S.V. Accelerated fracture healing. J Am Acad Orthop Surg 14, S145, 2006.
11. Tiyapatanaputi, P., Rubery, P.T., Carmouche, J., Schwarz, E.M., O'Keefe R.J., and Zhang, X. A novel murine segmental femoral graft model. J Orthop Res 22, 1254, 2004.
12. Yanoso-Scholl, L., Jacobson, J.A., Bradica, G., Lerner, A.L., Zuscik, M.J., Schwarz, E.M., O'Keefe, R.J., and Awad, H.A. Evaluation of polylactic acid/betatricalcium phosphate scaffolds for bone tissue engineering. J Biomed Mat Res A 2010 Aug 19 [Epub ahead of print].
13. Reynolds, D.G., Hock, C., Shaikh, S., Jacobson, J., Zhang, X., Rubery, P.T., et al. Micro-computed tomography prediction of biomechanical strength in murine structural bone grafts. J Biomech 40, 3178, 2007.
14. Bruder, S.P., Fink, D.J., and Caplan, A.I. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 56, 283, 1994.
15. Niu, X., Feng, Q., Wang, M., Guo, X., and Zheng, Q. Porous nano-HA/collagen/PLLA scaffold containing chitosan mi-crospheres for controlled delivery of synthetic peptide derived from BMP-2. J Control Release 134, 111, 2009.
16. Nie, H., Soh, B.W., Fu, Y.C., and Wang, C.H. Three-dimensional fibrous PLGA/HAp composite scaffold for BMP-2 delivery. Biotechnol Bioeng 99, 223, 2008.
17. Saito, A., Suzuki, Y., Kitamura, M., Ogata, S., Yoshihara, Y., Masuda, S., et al. Repair of 20-mm long rabbit radial bone defects using BMP-derived peptide combined with an alphatricalcium phosphate scaffold. J Biomed Mater Res A 77, 700, 2006.
18. Hu, Y., Zhang, C., Zhang, S., Xiong, Z., and Xu, J. Development of a porous poly(L-lactic acid)/hydroxyapatite/ collagen scaffold as a BMP delivery system and its use in healing canine segmental bone defect. J Biomed Mater Res A 67, 591, 2003.
19. Kofron, M.D., and Laurencin, C.T. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev 58, 555, 2006.
20. White, A.P., Vaccaro, A.R., Hall, J.A., Whang, P.G., Friel, B.C., and McKee, M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 31, 735, 2007.
21. Leach, J., and Bittar, R.G. BMP-7 (OP-1) safety in anterior cervical fusion surgery. J Clin Neurosci 16, 1417, 2009.
22. Brower, R.S., and Vickroy, N.M. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. Spine (Phila Pa 1976) 33, E653, 2008.
23. Allen, R.T., Lee, Y.P., Stimson, E., and Garfin, S.R. Bone morphogenetic protein-2 (BMP-2) in the treatment of pyo-genic vertebral osteomyelitis. Spine (Phila Pa 1976) 32, 2996, 2007.
24. Wong, D.A., Kumar, A., Jatana, S., Ghiselli, G., and Wong, K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 8, 1011, 2008.
25. Perri, B., Cooper, M., Lauryssen, C., and Anand, N. Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study. Spine J 7, 235, 2007.
26. Levicoff, E.A., Kim, J.S., Sobajima, S., Wallach, C.J., Larson, J.W., 3rd, Robbins, P.D., et al. Safety assessment of in-tradiscal gene therapy II: effect of dosing and vector choice. Spine (Phila Pa 1976) 33, 1509; discussion 17, 2008.
27. Haviernik, P., and Bunting, K.D. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Curr Gene Ther 4, 263, 2004.
28. Kho, S.T., Pettis, R.M., Mhatre, A.N., and Lalwani, A.K. Safety of adeno-associated virus as cochlear gene transfer vector: analysis of distant spread beyond injected cochleae. Mol Ther 2, 368, 2000.
29. Canalis, E., Giustina, A., and Bilezikian, J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357, 905, 2007.
30. Skripitz, R., and Aspenberg, P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br 83, 437, 2001.
31. Andreassen, T.T., Ejersted, C., and Oxlund, H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14, 960, 1999.
32. Nakajima, A., Shimoji, N., Shiomi, K., Shimizu, S., Moriya, H., Einhorn, T.A., et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17, 2038, 2002.
33. Andreassen, T.T., Willick, G.E., Morley, P., and Whitfield, J.F. Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 74, 351, 2004.
34. Komatsubara, S., Mori, S., Mashiba, T., Nonaka, K., Seki, A., Akiyama, T., et al. Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36, 678, 2005.
35. Manabe, T., Mori, S., Mashiba, T., Kaji, Y., Iwata, K., Komatsubara, S., et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 40, 1475, 2007.
36. Nakazawa, T., Nakajima, A., Shiomi, K., Moriya, H., Ein-horn, T.A., and Yamazaki, M. Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 37, 711, 2005.
37. Pettway, G.J., Meganck, J.A., Koh, A.J., Keller, E.T., Goldstein, S.A., and McCauley, L.K. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42, 806, 2008.
38. Pettway, G.J., Schneider, A., Koh, A.J., Widjaja, E., Morris, M.D., Meganck, J.A., et al. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 36, 959, 2005.
39. Kim, C.H., Takai, E., Zhou, H., von Stechow, D., Muller, R., Dempster, D.W., et al. Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res 18, 2116, 2003.
40. Lu, Z., and Zreiqat, H. Betatricalcium phosphate exerts osteoconductivity through alpha2beta1 integrin and downstream MAPK/ERK signaling pathway. Biochem Biophys Res Commun 394, 323, 2010.
41. Childress, P., Robling, A.G., and Bidwell, J.P. Nmp4/CIZ: road block at the intersection of PTH and load. Bone 46, 259, 2010.
42. Bellido, T., Ali, A.A., Gubrij, I., Plotkin, L.I., Fu, Q., O'Brien, C.A., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146, 4577, 2005.
43. Van Bezooijen, R.L., Roelen, B.A., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199, 805, 2004.
44. Kakar, S., Einhorn, T.A., Vora, S., Miara, L.J., Hon, G., Wigner, N.A., et al. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 22, 1903, 2007.
45. Esbrit, P., Alvarez-Arroyo, M.V., De Miguel, F., Martin, O., Martinez, M.E., and Caramelo, C. C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11, 1085, 2000.
46. Deckers, M.M., Karperien, M., van der Bent, C., Yamashita, T., Papapoulos, S.E., and Lowik, C.W. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology 141, 1667, 2000.
47. Diamond, A.G., Gonterman, R.M., Anderson, A.L., Menon, K., Offutt, C.D., Weaver, C.H., et al. Parathyroid hormone hormone-related protein and the PTH receptor regulate an-giogenesis of the skin. J Invest Dermatol 126, 2127, 2006.